Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Mayo Clin Proc. 2019 Oct 13;94(11):2220–2229. doi: 10.1016/j.mayocp.2019.05.031

Figure 1. Discontinuation of ACE-I/ARB among incident users, by CKD stage at baseline.

Figure 1.

Abbreviations: ACE-I/ARB, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, or their combination; CKD, chronic kidney disease